Recently Featured

Super Bowl, Winter Olympics Defined TV Drug Ad Spending in February, Led by AbbVie’s Rinvoq

March 28, 2026
February saw a significant surge in pharmaceutical television advertising, largely driven by the Super Bowl and the Winter Olympics, with AbbVie’s Rinvoq emerging as the top spender. This strategic investment in high-profile sporting events underscores the importance of aligning product promotion with major cultural moments that attract large audiences. The data reveals that nearly all…

Lilly Appoints Anne-Virginie Eggimann as Chief Development Officer for Regenerative Medicine

March 28, 2026
Eli Lilly has appointed Anne-Virginie Eggimann as the new chief development officer for its regenerative medicine unit, a strategic move aimed at bolstering its capabilities in this rapidly evolving field. Eggimann previously served at Flagship Pioneering and bluebird bio, where she honed her expertise in developing innovative therapies over the past three and a half…

Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal

March 28, 2026
Alnylam Pharmaceuticals has entered into a significant $1.23 billion deal with Tenaya Therapeutics focused on cardiovascular target discovery. This collaboration marks a strategic move for Alnylam as it aims to replicate the commercial success of its blockbuster ATTR-CM therapy, Amvuttra, which has set a high standard in the treatment of transthyretin amyloidosis. The partnership with…

J&J Secures FDA Approval for Tecvayli-Darzalex Combination in Relapsed/Refractory Multiple Myeloma

March 28, 2026
Johnson & Johnson has received approval from the US FDA for the combination therapy of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab) for adults suffering from relapsed or refractory multiple myeloma (RRMM). This decision marks a significant advancement in treatment options for a patient population that has limited alternatives after multiple lines of therapy. The approval…

Ongoing Cases